Ensysce Biosciences vs Entrada Therapeutics
Entrada Therapeutics is the larger business, with $25.4m of revenue in fiscal 2025 against $5.1m for Ensysce Biosciences (5.0 times as much). Ensysce Biosciences grew faster (-2.8% against -87.9%). Ensysce Biosciences kept more of each dollar of sales as profit: a net margin of -200.8% against -565.5%. Entrada Therapeutics carries less debt relative to equity (0.0% against 9.5%).
| Latest fiscal year | Ensysce BiosciencesENSC, 2025 | Entrada TherapeuticsTRDA, 2025 |
|---|---|---|
| Revenue | $5.1m | $25.4m |
| Revenue growth | -2.8% | -87.9% |
| Net income | −$10.2m | −$144m |
| Operating margin | -202.1% | -621.1% |
| Net margin | -200.8% | -565.5% |
| Return on equity | — | -39.1% |
| Free cash flow | −$7.9m | −$130m |
| Cash | $4.3m | $90.4m |
| Total debt | $306,708 | $0 |
| Debt to equity | 9.5% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 152 |
| Market value | $5.9m | $185m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 2 buys, 0 sales | 17 buys, 44 sales |